Format

Send to

Choose Destination
Transfusion. 2019 Apr 15. doi: 10.1111/trf.15309. [Epub ahead of print]

The prevalence of human T-cell leukemia virus in blood donors in China.

Li L1,2, Ou S3, Huang C4, Zhou X5, Ge H6, Li J7, Zeng J8, Zhou A9, He L10, Xu Q11, Wu J12, Li L13, Wang C14, Zang L15, Huang L6, Niu L16, Han H17, Zhang G18, Wan J19, Wang F7, Xu T20, Zhao B21, Qian L22, Wu Y1,23, Liu Z1,2.

Author information

1
Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan, China.
2
Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, Sichuan, China.
3
Xiamen Blood Center, Xiamen, Fujian, China.
4
Jiangsu Blood Center, Nanjing, Jiangsu, China.
5
Anhui Blood Center, Hefei, Anhui, China.
6
Beijing Blood Center, Beijing, China.
7
Liaoning Blood Center, Shenyang, Liaoning, China.
8
Shenzhen Blood Center, Shenzhen, Guangdong, China.
9
University of California, Berkeley, Berkeley, California.
10
Hefei Tian Yi Biotech Institute Co., Ltd., Hefei, Anhui, China.
11
Maanshan Blood Center, Maanshan, Anhui, China.
12
Wuhu Blood Center, Wuhu, Anhui, China.
13
Anqing Blood Center, Anqing, Anhui, China.
14
Bengbu Blood Center, Bengbu, Anhui, China.
15
Dalian Blood Center, Dalian, Liaoning, China.
16
Changzhi Blood Center, Changzhi, Shanxi, China.
17
Hainan Blood Center, Haikou, Hainan, China.
18
Changsha Blood Center, Changsha, Hunan, China.
19
Urumchi Blood Center, Urumchi, Xinjiang, China.
20
Yili Blood Center, Yili, Xinjiang, China.
21
Nanchong Blood Center, Nanchong, Sichuan, China.
22
Deyang Blood Center, Deyang, Sichuan, China.
23
Bloodworks Northwest, Seattle, Washington.

Abstract

BACKGROUND:

China has not yet incorporated routine human T-lymphotropic virus (HTLV)-1/2 blood donor screening, even though HTLV has been reported in the southeastern coastal region. This study was conducted to investigate the prevalence of HTLV in five major regions across of China.

METHODS:

From January 2016 to December 2017, blood samples were collected in 20 blood centers located in different regions of China. These samples were screened for HTLV-1/2 antibodies using enzyme-linked immunosorbent assay (ELISA). If the test samples were reactive, the samples were confirmed with a western blot (WB) assay. If the results of WB were indeterminate, the donor was interviewed after a minimum lapse of 8 weeks. All follow-up samples from donors were tested for anti-HTLV-1/2 with ELISA and WB.

RESULTS:

There were 875,453 donor samples tested for anti-HTLV-1/2 by ELISA. In all, 365 samples tested negative, 22 samples tested positive by WB, and 14 samples with HTLV status undetermined due to being lost to follow-up. The prevalences were 11.09, 5.96, 3.16, 2.88 and 0.98 per 100,000 in Xiamen, Changsha, Beijing, Shenzhen, and Nanjing blood center, respectively. The prevalences were 0 per 100,000 for all 15 other blood centers. There was significant differences in the prevalence of HTLV in different regions of China (p = 0.0011).

CONCLUSION:

In China, HTLV-1 confirmed positive donors are mainly from southeastern coastal areas. It may be necessary to conduct HTLV screening in these areas to reduce the risk of transfusion-transmitted HTLV.

PMID:
30985961
DOI:
10.1111/trf.15309

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center